CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA ...Middle East

SHANGHAI, March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China's National...

Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA )

Also on site :

• US, China call for restraint as India-Pakistan tensions escalate
• Wynonna Judd Fans Declare Her a 'Trailblazer' As She Celebrates Special Honor
• NYT Mini Crossword Answers, Hints for Saturday, May 10, 2025